Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months

Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues.

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues. Q3 2025 revenue reached $17.1M (+38% YoY); gross profit $2.6M (+116%) with a 15.21% margin; cash rose to $4.63M from $0.66M.

The company said U.S. rollout of NOOR collagen is on track, produced in GMP/FDA-registered facilities, and projected to exceed $12M revenue within 12 months with ~75% gross margins.

Positive

• Revenue $17.1M in Q3 2025, up 38% YoY
• Gross profit $2.6M, a 116% increase with 15.21% margin
• Cash position $4.63M, up from $0.66M at Q2 2025
• NOOR U.S. projected >$12M revenue within 12 months at ~75% gross margin
• Products manufactured in U.S. GMP/FDA-registered facilities, reducing tariff and logistics risk

Negative

• None.

Argus Apr 10 session

+3.45% close to close Open Argus

Details

News Market Reaction – COSM

On Apr 10, the day this news came out, COSM closed 3.45% above the previous close.

Data tracked by StockTitan Argus for the Apr 10 session.

Market Context

This announcement underscores that geopolitical tensions in the Middle East have had negligible oper...

Analysis

This announcement underscores that geopolitical tensions in the Middle East have had negligible operational impact while COSM reports record Q3 2025 revenue of $17.1 million, gross margin of 15.21%, and stronger cash of $4.63 million. Management reiterates expectations for NOOR U.S. revenue to exceed $12 million at roughly 75% gross margins over 12 months. Historically, similar crypto‑tagged updates generated modest and mixed price moves, so investors may focus on forthcoming FY 2025 results and execution of the U.S. expansion plan.

Key Figures

Q3 2025 revenue: $17.1 million Q3 2025 revenue growth: 38% year-over-year Q3 2025 gross profit: $2.6 million +5 more

Q3 2025 revenue

$17.1 million

All-time high quarterly revenue, 38% year-over-year increase

Q3 2025 revenue growth

38% year-over-year

Growth rate vs. prior-year quarter

Q3 2025 gross profit

$2.6 million

Gross profit more than doubled, up 116%

Q3 2025 gross margin

15.21%

Record gross margin for the company

Adjusted EBITDA change

74% improvement

Q3 2025 vs prior period

Cash position

$4.63 million

End of Q3 2025 vs $0.66 million at end of Q2 2025

NOOR projected revenue

>$12 million

Expected from NOOR collagen in U.S. within next 12 months

U.S. nutraceuticals market

$163.7 billion, 6.2% CAGR

2024 market size with projected CAGR through 2030

Previous Crypto Reports

5 past events · Latest: Apr 08

Same Type 5 events

1. Apr 08

   U.S. product launch

   24h Move

   +0.6%

   Announced Q2 2026 U.S. launch of Liv18 liver health supplement.

2. Apr 01

   Clinical validation

   24h Move

   +0.6%

   C-Scrub Wash 4% met EN 12791 standard, supporting hospital market expansion.

3. Mar 19

   Growth and guidance

   24h Move

   -0.4%

   Update on record growth, U.S. expansion, >$12M NOOR projection and LOI acquisition.

4. Mar 11

   Crypto treasury move

   24h Move

   +1.1%

   Purchased $600,000 of Bitcoin, lifting digital asset holdings to $3.1M.

5. Feb 19

   Asset valuation update

   24h Move

   -5.9%

   Highlighted ~$15M real estate value exceeding market cap and exploring monetization.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gmp-certified, fda-registered, adjusted ebidta, cagr

4 terms

gmp-certified regulatory

"manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities"

GMP-certified means a manufacturer has been inspected and approved for following Good Manufacturing Practice rules that ensure products are made consistently, safely, and meet quality standards. Think of it like a professional kitchen that follows strict recipes, cleanliness rules and checks so meals are safe every time. For investors, GMP certification lowers regulatory and product-risk, supports market access and brand trust, and can reduce the chance of costly recalls or production shutdowns.

fda-registered regulatory

"manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities"

An FDA-registered facility or product is one that has been listed with the U.S. Food and Drug Administration as required for certain medical devices, manufacturers, or establishments — like being entered in an official government directory. It does not mean the FDA has approved or certified safety or effectiveness, but it does mean the operation is subject to inspections and regulatory rules, which affects market access, investor risk assessment, and credibility with customers and partners.

adjusted ebidta financial

"record gross margin of 15.21%, while Adjusted EBITDA improved 74%"

Adjusted EBITDA is a company’s reported profit from its core operations before subtracting interest, taxes, and accounting for long-term costs like depreciation, further cleaned up by removing one-time, unusual, or non-cash items. Think of it as the operating cash-flow picture after erasing temporary blips so different periods and companies can be compared more easily; investors use it to judge underlying business performance, but it is not a standardized accounting measure and can be shaped by management choices.

cagr financial

"valued at $163.7 billion in 2024 and projected to grow at a 6.2% CAGR through 2030"

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company's operations, supply chain, or business performance. The Company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track.

Geopolitical Resilience Underpins Global Platform

Cosmos Health operates through a diversified international platform spanning Europe, North America, and other key regions. The conflict in the Middle East and recent geopolitical developments have had a negligible impact on the Company's operations. Management expects strong growth momentum to continue as the Company advances toward sustained profitability.

Record Revenue Momentum Continues

The Company's most recently reported quarter, Q3 2025, marked a new all-time high, with revenue reaching $17.1 million, a 38% increase year-over-year. Gross profit more than doubled, increasing 116% to $2.6 million, with a record gross margin of 15.21%, while Adjusted EBITDA improved 74%. Cash position strengthened to $4.63 million, up from $0.66 million at the end of Q2 2025.

This record-setting momentum has continued into subsequent periods. More detailed financial information will be provided in conjunction with the Company's fourth quarter and full-year 2025 results, expected shortly.

NOOR U.S. Expansion Accelerating

Sales of Sky Premium Life NOOR collagen in the United States are already underway, with the product manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company's commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.

The Company anticipates gross margins of approximately 75% from its U.S. operations, with NOOR collagen alone projected to generate more than $12 million in revenue within the next 12 months, positioned to benefit from the U.S. nutraceuticals market, valued at $163.7 billion in 2024 and projected to grow at a 6.2% CAGR through 2030, according to Grand View Research.

Greg Siokas, CEO of Cosmos Health, stated: "Our business has never been stronger. Q3 2025 marked our highest revenue, gross profit, and gross margin in the Company's history - and that momentum has continued. Our geographically diversified platform insulates us from regional disruptions, while the accelerating U.S. expansion of Sky Premium Life NOOR represents a transformational growth opportunity. We expect NOOR U.S. revenues to exceed $12 million within the next 12 months, at gross margins of approximately 75%, and we look forward to providing the full picture with our forthcoming 10-K filing."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life^®, Mediterranation^®, bio-bebe^®, C-Sept^® and C-Scrub^®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cosmos Health (COSM) report for Q3 2025 revenue and profit metrics?

Cosmos Health reported Q3 2025 revenue of $17.1M, up 38% year-over-year, and gross profit of $2.6M, a 116% increase. According to the company, gross margin reached 15.21% and Adjusted EBITDA improved 74%.

Has the Iran and Middle East conflict affected Cosmos Health's operations (COSM) as of April 10, 2026?

No—Cosmos Health said the conflict has had no material impact on operations, supply chain, or business performance. According to the company, its geographically diversified platform insulated operations from regional disruptions.

What are Cosmos Health's (COSM) cash and liquidity figures reported with Q3 2025 results?

Cosmos Health reported a strengthened cash position of $4.63M, up from $0.66M at the end of Q2 2025. According to the company, this improvement reflects operational momentum and improved Adjusted EBITDA.

What guidance did Cosmos Health (COSM) give for NOOR collagen U.S. sales and margins?

The company expects NOOR U.S. revenue to exceed $12M within 12 months with approximately 75% gross margins. According to the company, NOOR is manufactured in GMP, FDA-registered U.S. facilities to support this rollout.

How does Cosmos Health (COSM) describe its U.S. manufacturing and regulatory controls for NOOR?

Cosmos Health states NOOR is produced in GMP-certified, FDA-registered, and UL-audited U.S. facilities, intended to ensure product integrity and reduce tariff and cross-border logistical risk.

When will Cosmos Health (COSM) provide full-year 2025 financial details and filings?

The company said it will provide detailed financial information with its fourth quarter and full-year 2025 results and forthcoming 10-K filing. According to the company, those disclosures will present the full financial picture.